Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has a beta value of 0.96 and has seen 5.28 million shares traded in the recent trading session. The company, currently valued at $2.13B, closed the recent trade at $5.29 per share which meant it lost -$0.52 on the day or -8.93% during that session. The RXRX stock price is -133.65% off its 52-week high price of $12.36 and -5.86% below the 52-week low of $5.60. If we look at the company’s 10-day average daily trading volume, we find that it stood at 15.4 million shares traded. The 3-month trading volume is 23.01 million shares.
The consensus among analysts is that Recursion Pharmaceuticals Inc (RXRX) is Buy stock at the moment, with a recommendation rating of 2.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Sporting -8.93% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RXRX stock price touched $5.29 or saw a rise of 21.75%. Year-to-date, Recursion Pharmaceuticals Inc shares have moved -21.73%, while the 5-day performance has seen it change -22.08%. Over the past 30 days, the shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have changed -29.55%. Short interest in the company has seen 86.42 million shares shorted with days to cover at 2.75.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 11.83% from the levels at last check today.. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -13.42% off the targeted high while a plunge would see the stock gain -13.42% from the levels at last check today..
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
The company’s shares have lost -26.21% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -35.28% over the past 5 years.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next earnings report on 2025-Feb-27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Insiders own 3.61% of the company shares, while shares held by institutions stand at 77.01% with a share float percentage of 79.90%. Investors are also buoyed by the number of investors in a company, with Recursion Pharmaceuticals Inc having a total of 415.0 institutions that hold shares in the company. The top two institutional holders are ARK INVESTMENT MANAGEMENT LLC with over 28.14 million shares worth more than $211.07 million. As of 2024-06-30, ARK INVESTMENT MANAGEMENT LLC held 11.6199% of shares outstanding.
The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 26.59 million shares as of 2024-06-30. The firm’s total holdings are worth over $199.42 million and represent 10.9787% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . As of Feb 28, 2025 , the former fund manager holds about 4.84% shares in the company for having 19.14 shares of worth $100.77 million while later fund manager owns 12.77 shares of worth $67.26 million as of Feb 28, 2025 , which makes it owner of about 3.23% of company’s outstanding stock.
